TargetBeta
TNFSF4
TNF superfamily member 4 · also OX-40L, gp34, CD252, TXGP1 · CD molecules
2 programs in company-led studies act on TNFSF4, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| amlitelimabrule | Sanofi | phase 3 | 195 running | – | ChEMBL |
| brivekimig | Sanofi | phase 2 | 65 running | TNF | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Alopecia Areata, 1 program
- Asthma, 1 program
- Celiac Disease, 1 program
- Colitis, Ulcerative, 1 program
- Crohn Disease, 1 program
- Dermatitis, Atopic, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Glomerulosclerosis, Focal Segmental, 1 program
- Hidradenitis Suppurativa, 1 program
- Immune System Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 17, 2026brivekimig · Sanofi · phase 2 · NCT06958536
- Sep 30, 2027amlitelimab · Sanofi · phase 3 · NCT06241118
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.